Akebia Therapeutics, Inc. Quarterly Cost of Revenue in USD from Q4 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Akebia Therapeutics, Inc. quarterly/annual Cost of Revenue history and growth rate from Q4 2018 to Q3 2024.
  • Akebia Therapeutics, Inc. Cost of Revenue for the quarter ending September 30, 2024 was $14.2M, a 21.4% decline year-over-year.
  • Akebia Therapeutics, Inc. Cost of Revenue for the twelve months ending September 30, 2024 was $61.5M, a 16.4% increase year-over-year.
  • Akebia Therapeutics, Inc. annual Cost of Revenue for 2023 was $74.1M, a 13.3% decline from 2022.
  • Akebia Therapeutics, Inc. annual Cost of Revenue for 2022 was $85.6M, a 43.2% decline from 2021.
  • Akebia Therapeutics, Inc. annual Cost of Revenue for 2021 was $151M, a 49.2% decline from 2020.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $61.5M $14.2M -$3.85M -21.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $65.3M $17M -$237K -1.37% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $65.6M $11.6M -$8.58M -42.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $74.1M $18.7M +$21.3M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $52.8M $18M -$20.3M -53% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $73.1M $17.3M -$1.32M -7.08% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $74.4M $20.2M -$11.2M -35.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $85.6M -$2.66M -$50.3M -106% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $136M $38.3M +$22.3M +140% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $114M $18.6M -$33.9M -64.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-28
Q1 2022 $147M $31.3M -$3.26M -9.43% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $151M $47.6M -$15.6M -24.7% Oct 1, 2021 Dec 31, 2021 10-K/A 2023-08-28
Q3 2021 $166M $15.9M -$14.4M -47.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $181M $52.5M -$122M -69.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $303M $34.6M +$6.89M +24.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $296M $63.2M +$25.1M +65.8% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-25
Q3 2020 $271M $30.3M -$7.92M -20.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $279M $175M +$137M +364% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $142M $27.7M -$3.54M -11.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $145M $38.1M +$30.4M +391% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 $115M $38.3M Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 $37.7M Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 $31.3M Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 $7.77M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.